Eurofins Technologies Launches New SENSIStrip Allergen Product Range: Quickly Detects Allergens That Must Be Labeled On Packaged Food

December 14, 2020

Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces the launch of the new SENSIStrip Allergen product range, which quickly detects allergens that must be labeled on packaged food products.

Managing food allergies usually means completely eliminating the allergen from one’s diet. To achieve this, consumers rely on clear labeling and traceability throughout the entire food production process, from raw material to the final product.

SENSIStrip Allergen kits are based on the concept of an immunoassay, an easy-to-use and quick method that requires only a few minutes of incubation time. This enables adequate allergen control at different stages of the food manufacturing process, across food matrices, rinse water, and equipment.

With low detection limits and accessibility (the kit does not require the expertise of highly-qualified staff to operate it), the SENSIStrip Allergen kits are the perfect tool to control potential cross-contamination with food allergens, allowing for quick screening of raw materials, the production process, and the final product. This avoids the external analyses and thus considerably reduces the time taken to release a food product batch to market.

The kits are provided with all the necessary and ready-to-use material to perform analysis across 20 individual tests per kit, on food matrices or environmental samples. In addition, an evaluation card is included to enable a semi-quantitative result, based on the intensity of the test line on the strip.

This new product range is a key component of Eurofins Technologies’ food allergen management and cleaning control monitoring solutions which, together with the comprehensive line of SENSISpec ELISA assays for allergen detection, demonstrate Eurofins Technologies’ commitment to providing high-quality test methods for food safety customers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”